Abbott’s XIENCE Sierra stent to be reimbursed through insurance in Japan
Abbott’s XIENCE Sierra, the newest generation of the company’s everolimus-eluting coronary stent, has been approved for national reimbursement in Japan.
The stent, which was approved in Europe late last year and in Japan on April 4, offers a new delivery system and more sizes to help physicians treat difficult-to-reach blockages, according to a press release.
"Extensive clinical data and 10 years of real-world experience with the XIENCE family of stents provide doctors with confidence that they are treating their patients with one of the safest stents available," Chuck Brynelsen, senior vice president of Abbott's vascular business, said in the release. "National reimbursement of XIENCE Sierra will provide people in Japan with greater access to this life-changing technology that can help them live their best lives."
The XIENCE Sierra is currently limited to investigational use in the United States.
Daniel joined TriMed’s Chicago editorial team in 2017 as a Cardiovascular Business writer. He previously worked as a writer for daily newspapers in North Dakota and Indiana.